Crohn's Disease and Colitis Trial, Recruiting NCT07123207 Sponsor: The Third Xiangya Hospital of Central South University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT07123207
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • You have been diagnosed with Crohn's disease according to recognised medical guidelines
  • You are currently being treated with a medication called Infliximab
  • Your Crohn's disease is currently in an active (flaring) stage, based on specific medical scoring measures (confirm with trial site)
  • You are willing to take part in the study and sign a consent form

Who may not be able to join:

  • Your liver test results (specifically ALT, AST, or bilirubin levels) are more than twice the normal level
  • Your kidneys are not filtering blood well enough, based on a specific kidney function test (confirm with trial site)
  • You currently have a serious active infection in your gut or elsewhere that requires antibiotic or antiviral treatment
  • You have intestinal tuberculosis, another chronic gut infection, or a cancerous tumour in the intestines
  • You are currently pregnant or breastfeeding
  • You have diabetes, or your blood sugar levels during screening are above a certain level (fasting blood sugar above 7.0 mmol/L or a blood sugar average test called HbA1c above 6.5%)
  • You have a serious mental health condition, or problems with drug or alcohol misuse that would make it difficult to take part in the study
  • You have taken part in another clinical trial within the month before joining this study
  • The trial team decides that any other health condition or circumstance makes it unsuitable for you to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiaoyan Wang, MD, The Third Xiangya Hospital of Central South University

Phone: +8613974889301

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Third Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
4 August 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Endoscopic remission rate; Clinical remission rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov